the only other thing I would add is that there's more flexibility in terms of the regulatory approval pathway given there's no existing treatment for either PMS or Pitt Hopkins and NNZ2591 safety profile is good too.
The market was still a bit doubtful of the FDA approval even after successful phase 3 for DAYBUE including the analyst from Evans and Partners due to the side effects but I maintained that the approval threshold was low simply because there's no existing approved treatment option for Retts
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.10 |
Change
-0.800(5.76%) |
Mkt cap ! $1.629B | |||
| Open | High | Low | Value | Volume |
| $13.95 | $13.96 | $12.88 | $9.534M | 725.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 266 | $13.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.15 | 1619 | 2 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |